CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Matthew Raymond Smith, Josep M. Piulats, Tilman Todenhöfer, Jae-Lyun Lee, Jose Angel Arranz Arija, Laura Mazilu, Arun Azad, Teresa Alonso-Gordoa, Ursula Brigid McGovern, Atish Dipankar Choudhury, Dingwei Ye, Hiroyoshi Suzuki, Rana R. McKay, Steven Ades, Aude Flechon, Christopher Michael Pieczonka, Maarten Hulstijn, Andrew Lithio, Karim Nacerddine, Neeraj Agarwal
Institutions: Harvard University, Massachusetts General Hospital, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Praxis für Humangenetik Tübingen, Asan Medical Center, University of Ulsan, Hospital General Universitario Gregorio Marañón, Peter MacCallum Cancer Centre, Hospital Universitario Ramón y Cajal, University College Hospital, Dana-Farber Cancer Institute, Fudan University Shanghai Cancer Center, Toho University, Toho University Medical Center Sakura Hospital, University of California San Diego, University of Vermont, Centre Léon Bérard, Eli Lilly (United States), Huntsman Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Eli Lilly and Company
OpenAlex ID: W4399394897